Introduction
Sialic acids (Sias) are a family of negatively charged monosaccharides that frequently terminate sugar chains found on vertebrate cell surface glycoproteins and glycolipids. N-acetylneuraminic acid (Neu5Ac) is a major sialic acid in vertebrates (Angata and Varki, 2002; Traving and Schauer, 1998; Troy, 1992) . One common natural derivative of Neu5Ac is N-glycolylneuraminic acid (Neu5Gc), which is equally abundant on the cell surfaces of many mammalian tissues, including those of the great apes . All humans have a unique inactivating homozygous mutation in CMP-Neu5Ac hydroxylase (CMAH), eliminating the enzymatic activity that generates CMP-Neu5Gc from CMP-Neu5Ac (Chou et al., 1998; Irie et al., 1998) . The CMAH mutation was caused by an Alu replacement event (Hayakawa et al., 2001 )~2.5±3 million years ago (mya) (Chou et al., 2002) and resulted in the absence of Neu5Gc and a secondary increased level of Neu5Ac on human cell surfaces Varki, 2002) .
Mammalian cell±expressed Sias can be recognized by organism-extrinsic receptors, like viral hemagglutinins and bacterial toxins, as well as by organism-intrinsic receptors, such as the Siglecs (Sia-recognizing Ig-like lectins) and selectins (Angata and Brinkman-Van der Linden, 2002; Angata and Varki, 2002; Crocker, 2002; Crocker and Varki, 2001; Karlsson, 1998; Rosen and Bertozzi, 1994) . There are some known examples wherein the single oxygen atom difference between Neu5Ac and Neu5Gc can markedly affect such recognition processes (Angata and Brinkman-Van der Linden, 2002; Angata and Varki, 2002; Blixt et al., 2003; Collins et al., 1997; Karlsson, 1998; Kelm et al., 1994) . Thus human Sia-recognizing receptors, such as Siglecs, became candidates for evolutionary change following the human-specific loss of Neu5Gc and consequent increase in Neu5Ac expression.
Siglecs are cell surface type 1 transmembrane I±type lectins that are broadly classified into two groupsÐthe CD33/Siglec-3-related group (CD33rSiglecs, i.e., Siglecs-3, and -5 through -11 in humans) that are clustered in one genomic region (19q13.3±4), and another group, Siglecs-1, -2, and -4, that are more distantly related (Angata and Brinkman-Van der Linden, 2002; Crocker and Varki, 2001; Vyas et al., 2002) . The extracellular portion of the CD33rSiglecs consists of two to five immunoglobulin (Ig)-like domains, the most N-terminal one being a Sia binding V-set (antibody variable region-like) Ig-like domain (Angata and Brinkman-Van der Linden, 2002; Crocker and Varki, 2001) . Conserved features of this domain are required for Sia binding (Alphey et al., 2003) , and recognition specificity can be altered by relatively few amino acid changes (Yamaji et al., 2002) . These CD33rSiglecs are of interest with regard to evolutionary changes, because comparison of the syntenic genomic regions in humans and rodents show several differences (Angata et al., 2001a) . Furthermore, the human-specific loss of a critical arginine residue in a Siglec-like molecule (Siglec-L1; also within the CD33rSiglec gene cluster) abolished Sia binding after the last common ancestor with apes (Angata et al., 2001b) .
The selective expression of most CD33rSiglecs on granulocytes, monocytes, macrophages, and NK cells (Siglecs-3, -5, and -7±11) (Angata and Brinkman-Van der Linden, 2002; Crocker and Varki, 2001) implicates them in regulating innate immune functions mediated by these blood cell types. Involvement in cellular signaling is indicated by induced phosphorylation of conserved tyrosine residues on their cytosolic tails, which in turn causes association with the phosphatases SHP-1 and/or SHP-2 (Crocker and Varki, 2001; Taylor et al., 1999; Ulyanova et al., 2001) .
The amino-terminal V-set Sia-binding sites of CD33r-Siglecs on circulating innate immune cells are constitutivelỳ`m asked'' by interactions with Sias present on the same cell surface (Collins et al., 2002; Varki, 1998, 1999) .`U nmasking'' Siglecs expressed on human peripheral blood occurs on cellular activation (Razi and Varki, 1999) , and masking status is tied functionally to signaling events (Grobe and Powell, 2002) . It is unknown whether Siglecs simply oscillate between masked and unmasked states or bind to other Sias (not expressed on the same cell surface) after unmasking.
Despite all this information, the primary biological functions of CD33rSiglecs remain unknown. One possibility is that they are self-recognition molecules that prevent inappropriate activation of innate immune cells. An alternative hypothesis is that when unmasked they serve as detectors of invasive Sia-expressing bacteria (Crocker and Varki, 2001; Jones et al., 2003) . Several strains of pathogenic bacteria are known to express Neu5Ac on their surfaces (Angata and Varki, 2002; Troy, 1992; Vimr and Lichtensteiger, 2002) , thereby mimicking host cell surfaces and evading detection by both innate and adaptive immune systems (Jarvis, 1995; Vimr and Lichtensteiger, 2002; Wessels et al., 1989) . Unmasked Siglecs could thus provide a mechanism for the innate immune system cells to recognize these camouflaged bacteria. Sia-expressing pathogenic bacteria isolated from multiple mammalian species express Neu5Ac but never Neu5Gc (Angata and Varki, 2002; Troy, 1992; Vimr and Lichtensteiger, 2002) . Thus the pathogen-recognition hypothesis predicts that CD33rSiglecs on cells of the innate immune system must recognize Neu5Ac.
Recent studies (Blixt et al., 2003; Sonnenburg et al., unpublished data) indicate that human CD33rSiglecs are relatively indiscriminate in binding both Neu5Ac and Neu5Gc. Although this competence of human CD33r-Siglecs for Neu5Ac binding is consistent with their postulated role as detectors of sialylated bacteria, we provide evidence suggesting that Neu5Ac recognition is actually a derived, human-specific condition. This condition apparently resulted from recent adaptive evolution away from the ancestral strong Neu5Gc preference still observed for great apes and is a logical consequence of human loss of Neu5Gc expression.
Results and discussion
Cloned chimpanzee and gorilla Siglec-9 differ from the human ortholog in showing a strong preference for Neu5Gc-containing ligands Given the diverse biological roles of Sias, loss of Neu5Gc in human evolution was likely accompanied by both positive and negative consequences, although eventual fixation of the causal CMAH mutation in humans suggests a net advantage. We reasoned that human Neu5Gc loss would have initially caused improper signaling if there was sudden unmasking of any Siglecs with a preexisting specificity for Neu5Gc. Current knowledge precludes defining the severity of such a signaling defect, but it would have necessarily been less severe than the original condition that allowed the CMAH mutation to rise in frequency. Subsequent selection for Neu5Ac binding capability would then have allowed restoration of human Siglecs to their constitutive masked state, relieving such a defect (and increasing the net advantage of the CMAH mutation).
To address the possibility that human Siglecs have evolved different Sia-binding specificity from those of great apes, we compared the Neu5Ac-and Neu5Gc-binding ability of human, chimpanzee, and gorilla Siglec-9, one member of the CD33rSiglecs that is expressed on monocytes and granulocytes. To investigate possible differences in binding specificity of Siglec-9, we cloned the N-terminal Sia-binding regions of chimpanzee and gorilla Siglec-9 and fused them to the Fc-region of human IgG, resulting in recombinant soluble chimeric proteins (Siglec-9-Fc). The Neu5Ac-versus Neu5Gc-binding properties of these molecules were compared to those of human Siglec-9-Fc (Figure 1 ). These binding assays clearly demonstrate that although human Siglec-9 binds both Neu5Ac and Neu5Gc, the chimp and gorilla orthologs strongly prefer Neu5Gc. These data are consistent with the hypothesis of functional adaptation in members of the human CD33rSiglecs to accommodate Neu5Ac-binding following human Neu5Gc-loss.
We also asked whether this human-specific increase in Neu5Ac-binding of Siglec-9 is evident when the recombinant molecules interact with natural cell surface glycans. Epstein-Barr virus±transformed B cells from humans (expressing 495% Neu5Ac on their surfaces) and orangutans (expressing~85% Neu5Gc) (Brinkman- Van der Linden et al., 2000) were probed with the recombinant Siglec-9-Fc molecules and binding measured by flow cytometry. Consistent with the enzyme-linked immunosorbent assay (ELISA) results, human Siglec-9-Fc bound both B cell lines well but preferred the Neu5Ac-expressing human B cells. In contrast, chimp and gorilla Siglec-9-Fcs displayed robust binding specifically to the Neu5Gc-rich cells (data not shown). Our results demonstrate that human Siglec-9 underwent significant functional adaptation after the evolutionary divergence from great apes.
Siglecs on circulating blood cells from human and apes show marked differences in binding Neu5Ac or Neu5Gc bearing probes To test if endogenously expressed CD33rSiglecs from the human, chimp, and gorilla display similar binding
differences observed for recombinant Siglec-9, we examined Sia binding of experimentally unmasked endogenous Siglecs expressed on native blood cells from these three species. Binding of soluble multivalent probes bearing Neu5Ac or Neu5Gc in either the alpha2-3 or alpha2-6 linkage (Angata et al., 2001b) was quantified by flow cytometry. Remarkable differences between human and great ape Siglecs were observed. Unmasked Siglecs on human monocytes (data not shown) and granulocytes bound probes bearing either Neu5Ac or Neu5Gc (Figure 2 , top). In striking contrast, the corresponding chimp cells showed strong binding to Neu5Gc (see arrows in Figure 2 , bottom), with no detectable binding to Neu5Ac-bearing probes, in agreement with the binding properties observed for recombinant Siglec-9. This strict Neu5Gc preference was also observed in blood samples from three other chimps and one gorilla (data not shown). The Sia binding observed by flow cytometry of human blood leukocytes represents a composite of the properties of at least five different CD33rSiglecs expressed on these cell types (Siglecs-3, -5, -7, -9, and -10) (Crocker and Varki, 2001 ), and we have recently found that great ape blood leukocytes also express these Siglecs (Hurtado-Ziola and Varki, unpublished data). Together these data suggest the ancestral state for the predominantly expressed ape neutrophil and monocyteassociated CD33rSiglecs was a strong preference for Neu5Gc, with human CD33rSiglecs subsequently undergoing functional adaptation to accommodate Neu5Ac binding in the absence of Neu5Gc.
The coevolution of human CD33rSiglec specificity with the human sialylation pattern, and the strong Neu5Gc-binding preference of chimp and gorilla CD33rSiglecs supports our previous findings Varki, 1998, 1999) that the natural functional ligands of these molecules are endogenous Sias. These data also indicate that CD33r-Siglecs do not function primarily to recognize invasive bacterial pathogens (which can express Neu5Ac, but never Neu5Gc). Indeed, the possibility must now be considered that some of these pathogens may be exploiting the recently evolved Neu5Ac binding ability of human Siglecs to assist in their invasion. Domain-specific differences between the sequences of the N-terminal regions of human and ape Siglec-9 The genomic structure of the N-terminal region of Siglec-9 within all three species is identical, with the first exon encoding the signal peptide and the Sia-binding V-set domain and the second exon encoding the adjacent Ig-like C2-set domain (antibody constant domain-like). Comparison of the N-terminal sequences (Figure 3) shows multiple amino acid differences specifically in the 124 amino acid V-set domain (human-chimp identity 94.4%; humangorilla identity 92.7%). In contrast, the 93 amino acids comprising the adjacent C2-set domains have the expected level of amino acid identity (~99% for human-chimp and human-gorilla) (Figure 3 ). This disparity in identity of the V-set domain and adjacent C2-set domain in interspecies comparisons is consistent with human Neu5Gc loss leading to selection for changes specific to the V-set domain that altered Sia binding specificity.
In further support of this, the 200-base-pair intron between the V-set and C2-set encoding exons displays 99.5±100% identity for all pairwise comparisons between the three species (see Appendix). The chimpanzee and gorilla V-set sequence also show a lower than expected amino acid identity (94.4%). However both still maintain Fig. 1. Chimpanzee and gorilla Siglec-9 differ from the human ortholog in showing a strong preference for Neu5Gc-containing ligands. ELISA plate assay in which human, chimp, or gorilla Siglec-9-Fc were captured in protein A±coated wells and probed with Sia-biotinylated-PAA probes bearing Neu5Ac (white bars) or Neu5Gc (black bars) linked a2-3 or a2-6 to a Galb1-4GlcNAc unit. Results are mean values AE SD of triplicates and are typical of three or more such experiments. Assays were performed as previously described (Angata et al., 2001a) . The human molecule studied was cloned from the ancestral allele (see text for discussion of human polymorphism). Domain-specific functional adaptation of human Siglec the strict Neu5Gc-binding preference, indicating that selective pressures other than Neu5Gc loss may have also affected great ape Siglec-9 V-set domains.
Evidence for adaptive evolution involving the V-set domain of Siglec-9 Pairwise comparisons of Siglec-9 V-set DNA sequences amongst the three genera show that the great majority (almost 80%) of total nucleotide differences are nonsynonymous (result in amino acid changes). Indeed, seven of the eight chimp-human base pair differences in the 372 base pairs encoding the V-set domain are nonsynonymous (Table I , see also Appendix). This bias in the Siglec-9 V-set domains suggests that these amino acid changes have been selected for. To quantitate this bias, the nonsynonymous substitution rate (dN) and the synonymous substitution rate (dS) were calculated. A dN/dS 41 indicates positive directional selection, and values closer to zero suggest purifying selection (Hughes and Nei, 1988; Messier and Stewart, 1997) . Table I shows the dN/dS values for humanchimp, human-gorilla, and chimp-gorilla comparisons of the Siglec-9 V-set or C2 -set domain. Although these values indicate that amino acid changes in the V-set domain are under selection in all three lineages, the dN/dS ratio of 2.28 between humans and chimps is clearly highest. In contrast to the evidence for positive selection in the V-set domains, low dN/dS ratios (0.12 between chimp and human) for the adjacent C2-set domains implicate purifying selection as the major evolutionary force acting on this domain. Although the small sizes of the regions involved preclude definitive statistical analyses of these differences, the high identity of a noncoding sequence immediately adjacent to the V-set encoding exon provides further evidence suggesting positive selection of amino acid±changing mutations specific to the Sia-binding V-set domain. In the case of humans, one of these selective forces was likely the loss of Neu5Gc and the subsequent need to allow Neu5Ac binding to restore the masked state. We have also sequenced 1.1 kb of the N-terminus in 20 human Siglec-9 alleles representing global population diversity (20 alleles from 3 continents: 8 African (4 Mbuti, 4 Biaka); 6 Europeans; and 6 Japanese; detailed data not shown). This analysis showed only one polymorphic nonsynonymous site in the V-set domain and no synonymous changes. This polymorphic site is not one of those already mentioned as specific to the hominid lineage. No polymorphisms were found in the C2-set domain, nor in the introns. These data confirm that all other nonsynonymous changes in the V-set domain were fixed in the hominid lineage prior to the common ancestor of modern humans. The single nonsynonymous polymorphism was found in 55% of the human alleles studied, with a moderate frequency of the heterozygous genotypic state. Although the small exon sizes preclude strong statistical conclusions about the nature of inter-and intraspecific selective pressures, the data are consistent with ongoing positive or recent balancing selection on the human Siglec-9 V-set domain.
Evidence for episodic selection within the V-set of Siglec-9 in hominoids When the Gorilla sequence is used as an outgroup, it is apparent that human Siglec-9 acquired approximately twice as many lineage-specific amino acid substitutions as chimpanzees since divergence from the Homo-Pan common ancestor, consistent with adaptive changes in human sialic acid biology (Figure 4 ). To explore this issue further, we sequenced the N-terminal region of Siglec-9 from a bonobo. The ancestors of bonobos (Pan paniscus) and chimpanzees (Pan troglodytes) were geographically separated~3.5 mya, due to the appearance of the Zaire (Congo) river (Myers Thompson, 2003) , and molecular data suggest the genetic divergence of these Pan species to be~2.5 mya (Horai et al., 1992) . Remarkably, despite the prolonged period of evolutionary independence (which represents almost half of the evolutionary time since the common ancestor of Homo and Pan), we found only one difference between the chimp and bonobo V-set sequences (i.e., only 13% of the total divergence between chimps and humans). This conservation between the Pan V-set domains contrasts with the divergences among the Pan, human, and gorilla clades (Figure 4 , left tree). On the other hand, the C2-set domain tree shows minimal divergences (Figure 4 , right tree). Comparison of these domain-specific trees illustrates the disparate selective pressures on these adjacent segments of Siglec-9. The V-set domain tree also indicates that rapid evolution is not a ubiquitous feature of this domain in African hominoids, as the bonobo and chimp are tightly clustered. Signal Peptide V-set C2-set Fig. 3 . Deduced amino acid sequences of N-terminal regions of human, chimpanzee, bonobo, and gorilla Siglec-9. Predicted amino acid sequences of the Siglec-9 N-terminal regions of human (Hsa), chimp (Ptr), bonobo (Ppa), and gorilla (Ggo) including the signal peptide and first two Ig-like domains (V-set and C2-set, respectively). Nonidentical residues are indicated with a white letter on black background. The presumed domain borders are indicated, and consensus N-glycosylation sites are underscored. All such potential sites between species have been conserved, indicating a possible role of N-glycans in the biology of these molecules. Complete nucleotide sequence data are presented in the Appendix and in submitted GenBank files.
Hsa MLLL LLPL LW GR ERAEGQTS KLL TMQSSVT V QEG LC VHV PC SF S Y P SH GW Ptr MLLL LLPL LW GR ERAEGQTS NLL TMQSSVM V QEG LC VHV PC SF S Y P SR GW Ppa MLLL LLPL LW GR ERAEGQTS NLL TMQSSVM V QEG LC VHV PC SF S Y P SH GW Ggo MLLL LLPL LW GR ERAEGQTS NLL TMQSSVT V QEG LC VHV PC SF S

Hsa IYPG PVVH GY WF REGANTDQ DAP VATNNPA R AVW EE TRD RF HL L G D PH TK Ptr IYPG PVVH GY WF REGANTDQ DAP VATNNPA R AVR EE TRD RF HL L G D PH TK Ppa IYPG PVVH GY WF REGANTDQ DAP VATNNPA R AVR EE TRD RF HL L G D PH TK
Hsa PGTL ESGC PQ NL TCSVPWAC EQG TPPMISW I GTS VS PLD PS TT R S S VL TL Ptr PGTL ESGC PQ NL TCSVPWAC EQG TPPMISW I GTS VS PLD PS TT H S S VL TL Ppa PGTL ESGC PQ NL TCSVPWAC EQG TPPMISW I GTS VS PLD PS TT H S S VL TL Ggo PGTL ESGC PQ NL TCSVPWAC EQG TPPTISW I GTS VS PLD PS TT R S S VL
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In interpreting the unusual pattern of V-set domain evolution, we cannot assign the ancestral state for any of the differences between Gorilla and the other species. Thus three explanations must be considered (all of which suggest intermittent or episodic selection among African hominoids). First, this domain may have been subjected to strong selection during the early period of the African hominoid divergences about 6±8 mya, and once again in the hominid lineage, after the divergence from Pan. Second, recent independent selection events may have occurred in the hominid and gorilla lineages, but not in the Pan species. Third, there may have been continual positive selection on the Siglec-9 V-set domain in African hominoids, which decreased specifically in the Pan lineage. Regardless of which of these possibilities is true, the dN/dS data in Table I indicate that the greatest degree of evolution has occurred in the hominid lineage, and our functional data suggest that loss of Neu5Gc was the major force driving this selection ( Figure 5 ). What selective pressures caused the other divergences, whether extant interspecies differences reflect ancient selective sweeps, and whether there are other functional consequences, are questions that remain to be answered. One possibility we are exploring is that other species-specific changes in sialylation might have driven some of the selection in the other lineages.
Indeed, very recent comparisons of the entire CD33rSi-glec gene cluster among human, chimp, baboon, mouse, and rat have revealed a general increase of nonsynonymous mutations within the V-set domain of these molecules (Angata et al., unpublished data) . Because the endogenous glycan landscape appears to be the major determinant guiding the specificity of these receptors during evolution, it is (Rozas and Rozas, 1999) , following the method of Nei and Gojobori (1986) . V-set C2-set Sia Fig. 4 . Phylogenetic analysis of the amino acids of the V-set and adjacent C2-set domains of Siglec-9 in humans and African apes. A single most parsimonious branch and bound phylogram for the amino acid sequence of each domain was inferred using PAUP* (version 4.0b10). Trees were rooted with the Gorilla sequence to determine polarity of the Homo-Pan mutations. The number of amino acid substitutions is indicated on the branches, and branches are drawn to scale. Amino acid position 125 was removed in the V-set domain analysis due to unique states in each genus that prevented establishment of an ancestral state. Because most nucleotide changes are nonsynonymous, a nucleotide-based tree (not shown) looks very similar. The inset shows schematically the amino-terminal V-set domain involved in binding sialic acids and the following C2-set domain.
Domain-specific functional adaptation of human Siglec not surprising that unique aspects of Sia expression within each species may select for binding specificity-altering mutations in the Sia-binding V-set domain. In certain cases (e.g., humans) drastic changes in CD33rSiglec specificity would be required to accommodate drastic changes in Sia expression, such as the loss of Neu5Gc. In other species, fine-tuning of CD33rSiglec specificity to subtle changes in Sia expression would be sufficient. Taken together, these speculations raise testable hypotheses regarding the differing specificity of CD33rSiglecs from different species.
Conclusions and perspectives
For human Siglec-9, we have directly shown functional adaptation towards Neu5Ac-binding, evidence of Siabinding domain-specific divergence from the African great apes and a bias of nonsynonymous substitutions within this domain consistent with positive selection for mutations affecting receptor functionality. Experimental probing of multiple CD33rSiglecs present on human, chimp, and gorilla blood cells (Figure 2) indicates that many of these human receptors may have undergone a similar humanspecific functional change, away from a strong preference for Neu5Gc. Indeed, in vitro binding studies do show significant binding of other recombinant human CD33rSiglecs (-3, -5, -7, and -10) to both Neu5Ac and Neu5Gc (Blixt et al., 2003; Sonnenburg et al., unpublished data) . Additionally, initial analyses of recombinant human and chimp Siglec-7 indicate multiple amino acid changes in the V-set domain, a strong chimp Siglec-7 preference for Neu5Gc, and a human Siglec-7 accommodation of Neu5Ac (Sonnenburg et al., unpublished data) . Overall, our data also indicate that endogenous Sias (rather than surface Neu5Ac molecules of bacterial pathogens) are the functional ligands of CD33rSiglecs. This in turn suggests that the endogenous Sia landscape is the major factor directing evolution of CD33rSiglec binding specificity. Meanwhile, it is possible that some of Neu5Ac-expressing pathogens are actually exploiting the recently evolved Neu5Ac binding ability of human Siglecs.
We have also mapped the amino acid differences between human and chimp for Siglec-7 and -9 onto the available Siglec-7 V-set structure (Alphey et al., 2003) and found no obvious changes that would rationally explain the observed difference in binding specificity (Sonnenburg et al., unpublished data) . Although one or two amino acid changes could potentially change Siglec specificity, it is also possible that the observed differences are the cumulative result of several mutations that altered the Sia-binding pocket. This is supported by the observation that only 1 of the 13 sites of amino acid differences in human and chimp Siglec-7 and Siglec-9 V-set domains is in common, and this site does not appear to directly interact with the sialic acid (Sonnenburg et al., unpublished data) . Overall, the human change can be best characterized not as a specific switch from Neu5Gc to Neu5Ac preference but as a relaxation of specificity to accommodate Neu5Ac binding, without loss of Neu5Gc binding. Thus human Siglec-7 and -9 have accommodated Neu5Ac binding by distinct molecular strategies, suggesting that many of the V-set amino-acid differences that distinguish the human and chimp orthologs are required for the differences in observed binding properties. Together, these facts make it rather difficult to predict which amino acid changes are responsible and design rational mutagenesis studies.
Few human proteins are known to have undergone rapid selection during anthropoid primate evolution (Enard et al., 2002; Goldberg et al., 2003; Johnson et al., 2001; Messier and Stewart, 1997; Nadezhdin et al., 2001; Wyckoff et al., 2000) . To our knowledge, none of these reports directly demonstrated biochemically human-specific functional adaptation, as we have done here. It remains to be seen if changes in CD33r-Siglec-binding specificity are the residual signature of a past selective sweep involving a pathogen that affected Sia biology, whether they are relevant to present human resistance or susceptibility to disease or if they had any secondary consequences for the evolution of other human-specific traits.
We also note that the evidence for rapid evolution in Siglec-9 is much less apparent when the human-chimp comparisons include both the highly conserved exon 2 and the divergent exon 1. The Siglec-9 dN/dS decreases from 2.28 to 0.67 when the C2-set domain is included with the V-set domain in the analysis. Indeed, analysis of the entire Siglec coding regions from human and chimp (an additional three exons) would likely yield a value that does not noticeably deviate from that expected under purifying selection. For example, the average dN/dS ratio for 19 other immunerelated genes of humans and chimpanzees is 0.45 (Chen et al., 2001) . Thus the evidence suggesting domain-specific accelerated evolution would have been overlooked in conventional comparisons using entire open reading frames or full-length cDNAs. With chimp genome sequencing now well under way (Fujiyama et al., 2002; Olson and Varki, 2003) , large-scale efforts to identify additional chimphuman genetic differences are anticipated. Because most genes will likely show only a few amino acid differences between the two species, our data caution that functionally significant genetic differences will be missed unless an exonby-exon comparative approach is taken, with an emphasis on the functionality of the protein domain(s) encoded by each exon. Based on the data from chimps and gorillas, the ancestral state of hominoid and hominid leukocytes must have been dominated by Siglecs that recognized and were masked primarily by cell surface Neu5Gc. Approximately 2.5±3 million years ago, multiple hominid Siglecs that bound Neu5Gc were suddenly unmasked by the loss of Neu5Gc. These Siglecs could either undergo adaptive accommodation of Neu5Ac binding to restore their masked state (e.g., Siglec-9 and multiple other CD33rSiglecs), or they could be retired by losing their ability to bind Sias altogether (Siglec-L1).
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